UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
cSCC is one of the most common cancers in the U.S. and globally
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Subscribe To Our Newsletter & Stay Updated
